Aside from MHC Class I, EMT-TFs have previously been shown to activate the inhibitory immune receptors killer Ig-like receptors (KIR) KIR3DL1, KIR2DL1, KIR2DL3, and KIR2DL4 [145], and repress activating immune-receptor natural killer group member D (NKG2D) ligands UL-16 binding protein (ULBP) 1 [146] and ULBP2 [147] on the tumor cell surface. This evidence concerns the gene KIR3DL1 and neoplasm.